Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Drug Discov Today Dis Mech
2012 Jan 01;91-2:e29-e33. doi: 10.1016/j.ddmec.2012.11.005.
Show Gene links
Show Anatomy links
TARGETING THE GENOTOXIC EFFECTS OF ESTROGENS.
Montano MM
,
Krishnamurthy N
,
Sripathy S
.
???displayArticle.abstract???
Our studies indicate that expression of antioxidative stress enzymes is upregulated by Selective Estrogen Receptor Modulators (SERMs) in breast epithelial cell lines, providing protection against the genotoxic effects of estrogens and against estrogen-induced mammary tumorigenesis. This upregulation of antioxidative stress enzymes requires Estrogen Receptor beta (ERβ) and human homolog of Xenopus gene which Prevents Mitotic Catastrophe (hPMC2). Further studies indicate that hPMC2 has a functional exonuclease domain that is required for upregulation of antioxidative stress enzymes by SERMs and repair of estrogen-induced abasic sites.
Ansell,
In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens.
2004, Pubmed
Ansell,
In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens.
2004,
Pubmed
Bianco,
Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
2003,
Pubmed
Cavalieri,
Estrogens as endogenous genotoxic agents--DNA adducts and mutations.
2000,
Pubmed
Cavalieri,
Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer.
2011,
Pubmed
Chang,
Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.
2006,
Pubmed
Dawling,
In vitro model of mammary estrogen metabolism: structural and kinetic differences between catechol estrogens 2- and 4-hydroxyestradiol.
2004,
Pubmed
Decensi,
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
2003,
Pubmed
Decensi,
Biologic activity of tamoxifen at low doses in healthy women.
1998,
Pubmed
Dowers,
Bioactivation of Selective Estrogen Receptor Modulators (SERMs).
2006,
Pubmed
Fan,
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.
2001,
Pubmed
Gaikwad,
Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones.
2007,
Pubmed
Garcia,
Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells.
1992,
Pubmed
Hachey,
Sequential action of phase I and II enzymes cytochrome p450 1B1 and glutathione S-transferase P1 in mammary estrogen metabolism.
2003,
Pubmed
Hadi,
Determinants in nuclease specificity of Ape1 and Ape2, human homologues of Escherichia coli exonuclease III.
2002,
Pubmed
Helbock,
8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage.
1999,
Pubmed
Hiraku,
Catechol estrogens induce oxidative DNA damage and estradiol enhances cell proliferation.
2001,
Pubmed
Hopp,
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
2004,
Pubmed
Jefcoate,
Tissue-specific synthesis and oxidative metabolism of estrogens.
2000,
Pubmed
Ju,
A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.
2006,
Pubmed
Kim,
Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells.
2008,
Pubmed
Krishnamurthy,
The exonuclease activity of hPMC2 is required for transcriptional regulation of the QR gene and repair of estrogen-induced abasic sites.
2011,
Pubmed
,
Xenbase
Krishnamurthy,
Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis.
2012,
Pubmed
Lavigne,
The effects of catechol-O-methyltransferase inhibition on estrogen metabolite and oxidative DNA damage levels in estradiol-treated MCF-7 cells.
2001,
Pubmed
Lee,
Nrf2, not the estrogen receptor, mediates catechol estrogen-induced activation of the antioxidant responsive element.
2003,
Pubmed
Li,
Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo.
2004,
Pubmed
Lin,
Aldehydic DNA lesions induced by catechol estrogens in calf thymus DNA.
2003,
Pubmed
Mandlekar,
Mechanisms of tamoxifen-induced apoptosis.
2001,
Pubmed
Mann,
Estrogen receptor beta expression in invasive breast cancer.
2001,
Pubmed
Marti,
DNA repair nucleases.
2004,
Pubmed
Montano,
Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis.
2007,
Pubmed
Montano,
Identification and characterization of a novel factor that regulates quinone reductase gene transcriptional activity.
2000,
Pubmed
,
Xenbase
Moser,
The proofreading domain of Escherichia coli DNA polymerase I and other DNA and/or RNA exonuclease domains.
1997,
Pubmed
,
Xenbase
Murphy,
Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
2005,
Pubmed
Nakopoulou,
The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer.
2004,
Pubmed
Nunomura,
Oxidative damage is the earliest event in Alzheimer disease.
2001,
Pubmed
Nutter,
Cellular biochemical determinants modulating the metabolism of estrone 3,4-quinone.
1994,
Pubmed
Olevsky,
Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.
2008,
Pubmed
Owuor,
Antioxidants and oxidants regulated signal transduction pathways.
2002,
Pubmed
Palmieri,
Estrogen receptor beta in breast cancer.
2002,
Pubmed
Paruthiyil,
Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest.
2004,
Pubmed
Pilat,
Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6.
1996,
Pubmed
Saji,
Clinical significance of estrogen receptor beta in breast cancer.
2005,
Pubmed
Santen,
Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
2003,
Pubmed
Shen,
Bioreductive activation of catechol estrogen-ortho-quinones: aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity.
1997,
Pubmed
Shibutani,
Miscoding during DNA synthesis on damaged DNA templates catalysed by mammalian cell extracts.
1994,
Pubmed
Speirs,
Oestrogen receptor beta: what it means for patients with breast cancer.
2004,
Pubmed
Ström,
Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.
2004,
Pubmed
Tekmal,
Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities.
1996,
Pubmed
Xanthoudakis,
Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme.
1992,
Pubmed
Yager,
Estrogen carcinogenesis in breast cancer.
2006,
Pubmed
Yamamoto,
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
2005,
Pubmed
Zhu,
Functional role of estrogen metabolism in target cells: review and perspectives.
1998,
Pubmed
de Sousa,
Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors.
2006,
Pubmed
